Department of Cardiology, the Second Affiliated Hospital, Wenzhou Medical College, China.
J Zhejiang Univ Sci B. 2010 Aug;11(8):618-26. doi: 10.1631/jzus.B1001008.
In this study, we examined the protective effects of Danshen both on endothelial progenitor cells (EPCs) in patients with hypercholesterolemia and on in-vitro EPCs of healthy volunteers. In the clinical study, we randomly divided 24 subjects with hypercholesterolemia into two groups (the control group and the Danshen-treated group). At the end of two weeks of treatment, the EPC cellular functions of both groups were tested. The results indicated that, compared to the control group, EPCs in the Danshen-treated group showed significantly better cellular functions, which was manifested in the cloning number, the proliferation capacity, the number of EPC adhesions, and cell migration. In the subsequent in-vitro experiments, EPCs were treated with vehicle, oxidized low-density lipoprotein (Ox-LDL, 100 microg/ml), or Ox-LDL (100 microg/ml) plus different concentrations of Danshen (Danshensu 2, 10, or 50 microg/ml, respectively) for 24 h. The results showed that Danshen treatments can prevent the detrimental effects of Ox-LDL on EPC cellular functions measured by proliferation capacity (0.24+/-0.08, 0.37+/-0.11, 0.30+/-0.04 vs. 0.13+/-0.02, P<0.05, P<0.01, and P<0.01, respectively), and adhesion ability (63.00+/-11.60, 70.00+/-10.80, 85.50+/-11.41 vs. 40.50+/-6.85, all P<0.01). Compared to the group treated with Ox-LDL alone, Danshen treatment significantly decreased the lipid peroxidation end product malondialdehyde (MDA) [(4.34+/-0.54), (3.98+/-0.47), (3.46+/-0.31) vs. (5.57+/-0.64) nmol/ml, all P<0.01], increased the production of superoxide dismutase (SOD) [(29.74+/-0.71), (31.09+/-0.83), (30.41+/-0.65) vs. (14.76+/-3.99) U/ml, all P<0.01], and lowered the expression of interleukin-6 (IL-6) [(24.62+/-7.69), (27.04+/-3.14), (33.38+/-18.86) vs. (230.67+/-33.53) pg/ml, all P<0.01] and tumor necrosis factor-alpha (TNF-alpha) [(41.72+/-6.10), (17.02+/-6.82), (3.73+/-2.26) vs. (228.71+/-41.53) pg/ml, all P<0.01] in Ox-LDL treated EPCs. These results suggest that Danshen may exert a protective effect through its antioxidant and anti-inflammatory features.
在这项研究中，我们研究了丹参对高胆固醇血症患者的内皮祖细胞（EPC）和健康志愿者的体外 EPC 的保护作用。在临床研究中，我们将 24 名高胆固醇血症患者随机分为两组（对照组和丹参治疗组）。在两周的治疗结束时，测试了两组的 EPC 细胞功能。结果表明，与对照组相比，丹参治疗组的 EPC 细胞功能明显更好，表现在克隆数量、增殖能力、EPC 黏附数量和细胞迁移能力上。在随后的体外实验中，将 EPC 用载体、氧化型低密度脂蛋白（Ox-LDL，100μg/ml）或 Ox-LDL（100μg/ml）加不同浓度的丹参（丹参素 2、10 或 50μg/ml）处理 24 小时。结果表明，丹参处理可以预防 Ox-LDL 对 EPC 细胞功能的有害影响，如增殖能力（0.24±0.08、0.37±0.11、0.30±0.04 与 0.13±0.02，P<0.05、P<0.01 和 P<0.01）和黏附能力（63.00±11.60、70.00±10.80、85.50±11.41 与 40.50±6.85，均 P<0.01）。与单独用 Ox-LDL 处理的组相比，丹参处理显著降低了脂质过氧化终产物丙二醛（MDA）[（4.34±0.54）、（3.98±0.47）、（3.46±0.31）与（5.57±0.64）nmol/ml，均 P<0.01]，增加了超氧化物歧化酶（SOD）的产生[（29.74±0.71）、（31.09±0.83）、（30.41±0.65）与（14.76±3.99）U/ml，均 P<0.01]，并降低了白细胞介素-6（IL-6）[（24.62±7.69）、（27.04±3.14）、（33.38±18.86）与（230.67±33.53）pg/ml，均 P<0.01]和肿瘤坏死因子-α（TNF-α）[（41.72±6.10）、（17.02±6.82）、（3.73±2.26）与（228.71±41.53）pg/ml，均 P<0.01]在 Ox-LDL 处理的 EPC 中的表达。这些结果表明，丹参可能通过其抗氧化和抗炎特性发挥保护作用。
